189 results about "Extracellular matrix" patented technology

The present invention relates to a genetically engineered, CD19-specific chimeric T cell receptor and to immune cells expressing the chimeric receptor The present invention also relates to the use of such cells for cellular immunotherapy of CD9+ malignancies and for abrogating any untoward B cell function. The chimeric receptor is a single chain scFvFc:ζ receptor where scFvFc designates the extracellular domain, scFv designates the VH and VL chains of a single chain monoclonal antibody to CD19, Fc represents at least part of a constant region of an IgG1, and ζ represents the intracellular signaling domain of the zeta chain of human CD3. The extracellular domain scFvFc and the intracellular domain ζ are linked by a transmembrane domain such as the transmembrane domain of CD4. In one aspect, the chimeric receptor comprises amino acids 23-634 of SEQ I DNO:2. The present invention further relates to a method of making a redirected T cell expressing a chimeric T cell receptor by electroporation using naked DNA encoding the receptor.

An endoluminal prosthesis is provided for restricting fluid flow in a lumen. The endoluminal prosthesis has a tubular graft having a flexible body with at least one stent coupled thereto. The endoluminal prosthesis also includes a prosthetic valve coupled to the inside the tubular graft. The prosthetic valve can be made of a synthetic or an organic material, such as an extracellular matrix, and can operate to limit fluid flow in one direction, but allow fluid flow in the other direction.

Methods for producing secreted receptor analogs and biologically active peptide dimers are disclosed. The methods for producing secreted receptor analogs and biologically active peptide dimers utilize a DNA sequence encoding a receptor analog or a peptide requiring dimerization for biological activity joined to a dimerizing protein. The receptor analog includes a ligand-binding domain. Polypeptides comprising essentially the extracellular domain of a human PDGF receptor fused to dimerizing proteins, the portion being capable of binding human PDGF or an isoform thereof, are also disclosed. The polypeptides may be used within methods for determining the presence of and for purifying human PDGF or isoforms thereof.

Methods for producing secreted receptor analogs and biologically active peptide dimers are disclosed. The methods for producing secreted receptor analogs and biologically active peptide dimers utilize a DNA sequence encoding a receptor analog or a peptide requiring dimerization for biological activity joined to a dimerizing protein. The receptor analog includes a ligand-binding domain. Polypeptides comprising essentially the extracellular domain of a human PDGF receptor fused to dimerizing proteins, the portion being capable of binding human PDGF or an isoform thereof, are also disclosed. The polypeptides may be used within methods for determining the presence of and for purifying human PDGF or isoforms thereof.

Proteolytically stable small molecule β-turn peptidomimetic compounds have been identified as agonists or antagonists of neurotrophin receptors, such as TrkA. A compound of particular interest binds the immunoglobulin-like C2 region of the extracellular domain of TrkA, competes the binding of another TrkA ligand, affords selective trophic protection to TrkA-expressing cell lines and neuronal primary cultures, and induces the differentiation of primary neuronal cultures. The small β-turn peptidomimetic compounds of the invention can activate a tyrosine kinase neurotrophin receptor that normally binds a relatively large protein ligand. Such compounds that bind the extracellular domain of Trk receptors are useful pharmacological agents to address disorders where Trk receptors play a role, by targeting populations selectively.

The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of T lymphocytes, direct T cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific. Zetakine chimeric immunoreceptors represent a novel extension of antibody-based immunoreceptors for redirecting the antigen specificity of T cells, with application to treatment of a variety of cancers, particularly via the autocrin / paracrine cytokine systems utilized by human malignancy. In a preferred embodiment is a glioma-specific immunoreceptor comprising the extracellular targetting domain of the IL-13Rα2-specific IL-13 mutant IL-13(E13Y) linked to the Fc region of IgG, the transmembrane domain of human CD4, and the human CD3 zeta chain.

An embolic protection device for capturing emboli during treatment of a stenotic lesion in a body vessel is disclosed. In one example, the device comprises a filter and a filter portion made of an extracellular matrix circumferentially attached to the filter. The filter comprises a plurality of struts having first ends attached together at a center portion along a longitudinal axis. Each strut has an arcuate segment extending from the first end to a second end. The struts are configured to move between an expanded state for engaging with the body vessel and a collapsed state for filter retrieval or delivery. The filter portion is configured for allowing blood to flow therethrough and for capturing emboli when the filter is in the expanded state.

The invention discloses a medicine for preventing and treating Alzheimer disease. The medicine may comprise p75NTR-ECD of which the nucleotide sequence is represented by the nucleotide sequence SEQ ID No.1 in a sequence table and of which the amino acid sequence is represented by amino acid sequence SEQ ID No.2 in the sequence table. The medicine also may be p75NTR-ECD / Fc of which the nucleotide sequence is represented by the nucleotide sequence SEQ ID No.3 in the sequence table and of which the amino acid sequence is represented by amino acid sequence SEQ ID No.4 in the sequence table. The medicine has the effects of inhibiting Abeta from aggregating into oligomer and fiber, promoting the depolymerization of Abeta fibers, eliminating Abeta in head and resisting Abeta neurotoxicity. The invention provides the new medicine for treating Alzheimer disease, which has a plurality of effects and has a bright clinic application prospect.

This invention relates to detection of specific extracellular nucleic acid in plasma or serum fractions of human or animal blood associated with neoplastic or proliferative disease. Specifically, the invention relates to detection of nucleic acid derived from mutant oncogenes or other tumor-associated DNA, and to those methods of detecting and monitoring extracellular mutant oncogenes or tumor-associated DNA found in the plasma or serum fraction of blood by using rapid DNA extraction followed by nucleic acid amplification with or without enrichment for mutant DNA. In particular, the invention relates to the detection, identification, or monitoring of the existence, progression or clinical status of benign, premalignant, or malignant neoplasms in humans or other animals that contain a mutation that is associated with the neoplasm through detection of the mutated nucleic acid of the neoplasm in plasma or serum fractions. The invention permits the detection of extracellular, tumor-associated nucleic acid in the serum or plasma of humans or other animals recognized as having a neoplastic or proliferative disease or in individuals without any prior history or diagnosis of neoplastic or proliferative disease. The invention provides the ability to detect extracellular nucleic acid derived from genetic sequences known to be associated with neoplasia, such as oncogenes, as well as genetic sequences previously unrecognized as being associated with neoplastic or proliferative disease. The invention thereby provides methods for early identification of colorectal, pancreatic, lung, breast, bladder, ovarian, lymphoma and all other malignancies carrying tumor-related mutations of DNA and methods for monitoring cancer and other neoplastic disorders in humans and other animals.

The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In particular, thirty-five monoclonal antibodies reactive with PSMA expressed on the cell surface are exemplified. Additionally, the present invention relates to a novel protein variant (PSM′) of PSMA detected by a number of the antibodies of the invention. The hydrolase activity of PSMA and PSM′ allows the use of an immunoenzymatic assay for their detection.

The disclosure relates to a composition that is liquid at a temperature below the body temperature of a mammal and that solidifies at or above the body temperature of the mammal. The composition includes a thermally-desolubilizable polymer interspersed with a polymeric component of extracellular matrix and an encapsulated form of an amine compound (preferably an aminated component of extracellular matrix) that is de-encapsulated in the body of the mammal. The polymeric component is able to form covalent bonds with amine moieties in the aminated component, in one or more tissues in the body of the mammal, or both. Upon injection of a liquid suspension of these components into the body of the mammal, the thermally-desolubilizable polymer condenses, entrapping the polymeric component. The polymeric component binds covalently with a tissue in the body, and the aminated component end-caps the remaining reactive moieties of the polymeric component, forming a matrix at the site of injection. The disclosure also relates to uses of such compositions for forming a matrix on or within the body of a mammal. The compositions have a variety of uses, such as as bioadhesives, as sealants for ruptured tissues, as drug or imaging agent depots, or as mechanical cushions.

The invention provides isolated human DEC-205, its extracellular domain and functionally equivalent fragments thereof. Also provided are polynucleotides encoding same and vectors which include such polynucleotides. Further provided are methods of recombinantly producing human DEC-205, an extracellular domain thereof or a functionally equivalent fragment, and ligands that bind to human DEC-205 or a fragment thereof. Also provided are constructs for use in prophylaxis or therapy comprising such a ligand, human DEC-205 or an extracellular domain thereof coupled to a toxin or to an antigen capable of inducing a protective immune response in a patient.

Flowable matrix compositions and methods of their use and manufacture are provided. Exemplary compositions may include a flowable, syringeable, putty-like form of acellular human dermal matrix. In some cases, compositions may include a moldable acellular collagen extracellular matrix. In use, the matrix compositions can be used to fill or treat skin voids, channel wounds, and other soft tissue deficiencies.

The invention discloses a chitosan / polylysine in-situ gel and a preparation method thereof. The gel is an in-situ gel prepared from 1-5.5 percent by weight of sulfhydrylization chitosan and 0.1- 3.2 percent by weight of maleimide polylysine. The preparation method comprises the following steps of synthetizing the polylysine containing maleimide double bonds, and preparing a maleimide polylysine solution by taking a PBS (phosphate buffer solution) as a solvent; preparing a sulfhydrylization chitosan solution by taking the PBS as a solvent; and uniformly mixing the two solutions under the condition of physiological pH value to obtain the in-situ gel. The invention has the advantages that the preparation process is simple, and the prepared in-situ gel simulates the components, the structure and the functional characteristics of polysaccharide / polypeptide of a natural extracellular substrate, helps to increase histocompatibility of a material, promotes cell adhesion growth and has wide application prospects in the fields of tissue engineering and drug release.

The invention provides methods and compositions for diagnosing and treating subjects using EBPs. Specifically disclosed are peptides and peptidomimetics that bind selectively to the extracellular domain of ErbB2. These compositions are useful in the prevention and treatment of disorders characterized by ErbB2 overexpression (e.g., breast cancer).

Provided herein are methods and compositions for cardiac therapy. Such compositions include extracellular-matrix (ECM)-based products that can be used to support tissue repair. The compositions can be used for various purposes. In some cases, they can be introduced into a subject in order to preserve and / or repair damaged heart tissue.

A tissue-engineered epidermis is prepared from skin fibroblasts through obtaining the skin fibroblasts, preparing culture medium, amplifying culture, preparing extocytic matrix compound, preparing biologic scaffold, compounding the skin fibroblasts on the surface of biologic scaffold, and 3D culture. Its advantages are a certain elasticity and toughness, short culture time, and no obvious immunorejection reaction.

Disclosed is a device for sticking a plurality of cells to one basement in sequential arrays, which is characterized in that the upper surface of the basement is sequentially plated with a titanium adhesion layer, a golden layer, bands of mercaptan hydrophobic monolayer and bands of mercaptan hydrophilic monolayer, and the bands of mercaptan hydrophobic monolayer and the bands of mercaptan hydrophilic monolayer are parallel attached on the golden layer at intervals; the lower surface is provided with a second polydimethylsiloxane seal of a micro-groove unit; the micro-groove unit is composed of three parallel linear grooves; the ends of the grooves are provided with vertical through holes communicated with the grooves; the lower surface of the seal is coated on the surface of the basement with parallel bands of mercaptan hydrophobic monolayer and the bands of mercaptan hydrophilic monolayer; the linear grooves are perpendicular to the bands of mercaptan hydrophobic monolayer and the bands of mercaptan hydrophilic monolayer; and the golden surface of the basement is formed into a zone for the cells to be stuck on selectively. Substances (such as protein solution of the extra cellular matrix and polylysine solution, etc.), which facilitate the cells to be stuck, are injected into microflow pipes; after the cells are stuck selectively, different cell suspensions are injected into different pipes, and the cells are only stuck on the surfaces of the hydrophobic monolayer; then the seal is taken off, a plurality of different cell arrays are sequentially stuck on the basement.

The invention discloses a preparation method of an accellular epimatrix, the accellular epimatrix prepared by the preparation method and application of the accellular epimatrix in the field of preparation of medical instruments. The preparation method of the accellular epimatrix comprises the following steps: carrying out pretreatment on tissues and organs of mammals to obtain an analogy tissue precursor; separately carrying out virus inactivation treatment, DNA eliminating treatment, accellular treatment and defatting treatment on the analogy tissue precursor to obtain an accellular epimatrixprecursor; and successively carrying out gradient dewatering treatment and crosslinking treatment on the accellular epimatrix precursor, and finally shaping and drying to obtain the accellular epimatrix. By the gradient dewatering treatment, the accellular epimatrix precursor is soaked in organic matter solutions of which the concentrations are successively increased successively. According to the preparation method of the accellular epimatrix, the tissue precursor is treated through gradient dewatering, and thus, the orderly structure of collagenous fibers of the finally prepared accellularepimatrix is not damaged.

The invention discloses a serum-free culture medium used for culturing and amplifying skin keratinocytes in vitro. It adds amino acid, vitamin, hormone, growth gene, trace elements, and antioxidant, thus able to accelerate cell breeding and delay consenescence of the keratinocytes and makes them amplified in vitro by more times. Using the culture medium to make primary culture and subculture needs no trophoblast cells and no extracellular substrates like collagen, etc prepaved at the bottom of the culture bottle to help the keratinocytes adhere to the wall and grow.

The present invention concerns an antibody specific for human ALK (Anaplastic Lymphoma Kinase), in particular a scFv, a nucleic acid sequence encoding it, its production and its use as a pharmaceutical or for diagnostic purposes. Said antibody is suitable for the local treatment of tumors, in particular glioblastoma.

The invention provides a primary cell culture medium for culturing primary esophageal squamous carcinoma epithelial cells and containing a combination of an MST1 / 2 kinase inhibitor and a ROCK kinase inhibitor, and a culture method using the primary cell culture medium. According to the culture method, the primary cells are cultured on a culture vessel coated with extracellular matrigel by using the primary cell culture medium, so that the primary cells are rapidly proliferated. The cell model obtained by the primary cell culture medium and the primary cell culture method can be used for evaluating and screening curative effects of medicines.